Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

about

Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

Item

http://www.wikidata.org/entity/Q47663303

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

@en

Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

@nl

type

Item

label

Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

@en

Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

@nl

prefLabel

Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

@en

Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

@nl

P1476

Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

@en

P2093

Elisa Borella

http://www.w3.org/2001/XMLSchema#string

Giuseppe De Nicolao

http://www.w3.org/2001/XMLSchema#string

Italo Poggesi

http://www.w3.org/2001/XMLSchema#string

Letizia Carrara

http://www.w3.org/2001/XMLSchema#string

Paolo Magni

http://www.w3.org/2001/XMLSchema#string

Silvia Maria Lavezzi

http://www.w3.org/2001/XMLSchema#string

P2860

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Can the pharmaceutical industry reduce attrition rates?

Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.

Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.

Statistical issues in the analysis of adverse events in time-to-event data.

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.

P304

5-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17460441.2018.1388369

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28972401

http://www.w3.org/2001/XMLSchema#string